Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Melanoma Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

108 recruiting trials for Melanoma. Eligibility criteria explained in plain English.

TrialFinderData lists 108 Melanoma clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 1 is the largest group at 30% (18 studies); the largest phase groups are Phase 1: 18, Phase 1 / Phase 2: 16, Phase 2: 15, Phase 3: 7.

Research is led by M.D. Anderson Cancer Center (4), Memorial Sloan Kettering Cancer Center (3), Assistance Publique - Hôpitaux de Paris (3), among the most active sponsors registered for these trials.

The most frequently studied intervention is Nivolumab (drug, 8 trials), followed by Biospecimen Collection, binimetinib.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
108
Total Trials
108
Recruiting Now
7
Phase 3 Trials
10
Sponsors

Track Melanoma trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT03787056

Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients

Progastrin is a pro-hormone that, in physiological conditions, is maturated in gastrin in G cells of the stomach. The role of the gastrin is to stimulate the secretion of gastric...

Sponsor: Hospices Civils de LyonEnrolling: 41017 locations
RECRUITINGNCT00001823

Evaluation for NCI Surgery Branch Clinical Research Protocols

Background: The National Cancer Institute Surgery Branch (NCI-SB) has developed experimental therapies that involve taking white blood cells from patients' tumor or from their...

Sponsor: National Cancer Institute (NCI)Enrolling: 70001 location
RECRUITINGPhase 1 / Phase 2NCT00722228

Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors

This study is based on the finding that tumor cells that are grown in the laboratory can be modified in such a way that, when injected to the patient, they will stimulate his/her...

Sponsor: Hadassah Medical OrganizationEnrolling: 501 location
RECRUITINGPhase 1NCT05355701

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other...

Sponsor: PfizerEnrolling: 26720 locations
RECRUITINGPhase 1NCT03454035

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

This phase I study is designed to establish the safety, maximally tolerated dose (MTD) and recommended phase II dose (RP2D) of the ERK inhibitor ulixertinib (BVD-523) when...

Sponsor: UNC Lineberger Comprehensive Cancer CenterEnrolling: 451 location
RECRUITINGPhase 1NCT06910657

IDOV-Immune for Advanced Solid Tumors

This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not...

Sponsor: ViroMissile, Inc.Enrolling: 786 locations
RECRUITINGNCT05053230

A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer

The overarching long-term goal of the Integrative Medicine for Patient-reported Outcomes Values and Experience (IMPROVE) research program is to evaluate whether integrating a...

Sponsor: Memorial Sloan Kettering Cancer CenterEnrolling: 4807 locations
RECRUITINGPhase 3NCT07381972

Photodynamic Therapy Associated With Sonodynamic Therapy for the Treatment of Nodular Basal Cell Carcinoma

Evaluation of a therapeutic protocol based on the combination of photodynamic therapy and sonodynamic therapy, referred to as sonophotodynamic therapy. Since this new protocol is...

Sponsor: University of Sao PauloEnrolling: 1421 location
RECRUITINGNCT04424719

Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME)

Biomarkers search for early diagnosis of liver metastases in patients with uveal melanoma who benefit from a follow-up tailored to their personalized risk of relapse.

Sponsor: Institut CurieEnrolling: 7001 location
RECRUITINGPhase 1NCT05039801

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

To find the highest tolerable dose of IACS-6274 that can be given alone, in combination with bevacizumab and paclitaxel, or in combination with capivasertib to patients who have...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 541 location
RECRUITINGPhase 2NCT05512481

Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma

Neoadjuvant therapy is feasible in stage Ⅱ-Ⅲ melanoma, Carrelizumab combined with apatinib and temozolomide has synergistic antitumor effects and may improve pathological response.

Sponsor: Peking University Cancer Hospital & InstituteEnrolling: 601 location
RECRUITINGNCT06488365

In Vivo Liquid Biopsy of Melanoma (Cytophone)

The Cytophone is a first in the world patented system to identify and count single circulating melanoma cells in blood circulation inside the human body. The Cytophone has a...

Sponsor: CytoastraEnrolling: 1801 location
RECRUITINGPhase 1 / Phase 2NCT06727630

A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma

This is a Phase Ib, open-label study to determine the safety and preliminary efficacy of PRJ1-3024 in China subjects with unresectable local advanced or metastatic melanoma

Sponsor: Zhuhai Yufan Biotechnologies Co., LtdEnrolling: 401 location
RECRUITINGPhase 3NCT03567889

Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients

The trial aims to evaluate the efficacy of Daromun neoadjuvant treatment followed by surgery and adjuvant therapy to improve in a statistically significant manner the...

Sponsor: Philogen S.p.A.Enrolling: 18620 locations
RECRUITINGNCT02828202

Follow-up of a National Cohort of Melanoma Resectable Stage II, Stage III or IV Patients or Unresectable Primary

Prevention of melanoma can be efficient but mortality remains unchanged and 15 to 20% of patients still die from melanoma. Indeed metastatic melanoma is a heterogeneous highly and...

Sponsor: Assistance Publique - Hôpitaux de ParisEnrolling: 600020 locations
RECRUITINGPhase 2NCT07237100

Mirdametinib in Patients With Advanced NF1-mutant Melanoma

The goal of this clinical trial is to evaluate clinical efficacy of mirdametinib in patients with advanced NF1-mutant melanoma whose disease has progressed while on or after...

Sponsor: Kevin Kim, MDEnrolling: 101 location
RECRUITINGNCT05373823

MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors

This project, mySmartSkin (MSS), includes an innovative Type 1 hybrid effectiveness-implementation trial designed to enhance the effects of MSS and simultaneously assess key...

Sponsor: Rutgers, The State University of New JerseyEnrolling: 3851 location
RECRUITINGPhase 1 / Phase 2NCT04370587

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous...

This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in...

Sponsor: ImmVira Pharma Co. LtdEnrolling: 309 locations
RECRUITINGNCT06899789

Long-term Follow-up of Checkpoint Inhibitors-induced Ileo-colitis

This is a multicentric, observational study, including all European centres willing to take part. The multicentre nature is necessary for enhancing the generalisability of our...

Sponsor: Fondazione IRCCS Policlinico San Matteo di PaviaEnrolling: 2501 location
RECRUITINGPhase 3NCT05868707

OH2 Injection in Melanoma

To evaluate the efficacy of OH2 injection in patients with unresectable or metastatic melanoma who have failed at least second-line standard therapy, using investigator-selected...

Sponsor: Binhui Biopharmaceutical Co., Ltd.Enrolling: 34020 locations
RECRUITINGNCT06980740

Video-Tumorboard PLUS

In weekly expert meetings for oncological diagnostics and therapy, known as tumor boards, individual therapy recommendations are developed for cancer patients. By further...

Sponsor: University Hospital MuensterEnrolling: 3003 locations
RECRUITINGNCT07072143

An International Study on Pediatric Patients With Rare Tumors.

The PARTNER study is an international, prospective, observational study of paediatric patients with very rare tumours.

Sponsor: Azienda Ospedaliera di PadovaEnrolling: 62501 location
RECRUITINGNCT03860883

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may...

Sponsor: Melanoma and Skin Cancer Trials LimitedEnrolling: 299820 locations
RECRUITINGNCT04045691

Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment

BERING-MELANOMA - designed as a prospective, longitudinal, non-interventional study - investigates real-world effectiveness, quality of life, safety and tolerability of...

Sponsor: Pierre Fabre Pharma GmbHEnrolling: 75020 locations
RECRUITINGNCT07422779

Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia

The purpose of this study is to evaluate the efficacy of immunotherapy in the first-line treatment of metastatic melanoma in Slovenia and to investigate the association between...

Sponsor: Institute of Oncology LjubljanaEnrolling: 1001 location
RECRUITINGPhase 2NCT05136196

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or...

This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and...

Sponsor: National Cancer Institute (NCI)Enrolling: 15020 locations
RECRUITINGPhase 1NCT06022029

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients...

A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or...

Sponsor: OncoNano Medicine, Inc.Enrolling: 16816 locations
RECRUITINGPhase 2NCT04562129

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

The purpose of this study is to find out if the administration of Interleukin-2 concurrently with ipilimumab followed by Nivolumab will result in improved anti-cancer activity and...

Sponsor: H. Lee Moffitt Cancer Center and Research InstituteEnrolling: 291 location
RECRUITINGPhase 1 / Phase 2NCT05269381

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

This phase I/II trial tests the safety and tolerability of an experimental personalized vaccine when given by itself and with pembrolizumab in treating patients with solid tumor...

Sponsor: Mayo ClinicEnrolling: 1321 location
RECRUITINGPhase 1 / Phase 2NCT07339176

Intratumoral N17350 in Advanced Solid Tumors

The goal of this clinical trial is to learn if N17350 works to treat advanced solid tumors in adults. It will also learn about the safety of N17350 and help determine the best...

Sponsor: Onchilles Pharma IncEnrolling: 2752 locations
RECRUITINGPhase 1NCT07376707

A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic...

This is a Phase 1, multicenter, open-label, two-parts, FIH study to evaluate the tolerability, safety, PK/PD, and preliminary antitumor activity of TGI-5 as monotherapy and in...

Sponsor: Hefei TG ImmunoPharma Co., Ltd.Enrolling: 1941 location
RECRUITINGEarly Phase 1NCT07586904

Efficacy and Safety of Neoadjuvant Cadonilimab Plus High-Dose Recombinant Human Interferon α1b in Stage III/IV Melanoma.

1. Primary Objective To evaluate the efficacy and safety of cadonilimab in combination with high-dose recombinant human interferon α1b injection as neoadjuvant therapy in...

Sponsor: Xijing HospitalEnrolling: 101 location
RECRUITINGPhase 1NCT06889766

NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma

A single center, dose escalaion, Phase I clinical trial to demonstrate safety and efficacy of LauT-1, autologous "New York Esophageal Squamous Cell Carcinoma-1 T-Cell Receptor...

Sponsor: Centre Hospitalier Universitaire VaudoisEnrolling: 92 locations
RECRUITINGPhase 1 / Phase 2NCT01638676

A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients

The main purpose of this study is to evaluate the safety of Vemurafenib in combination with Metformin in melanoma patients. The phase II part of the study will also evaluate the...

Sponsor: University of LouisvilleEnrolling: 551 location
RECRUITINGNCT07223411

Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in...

This translational study will examine the immune effector responses of patients who received a two-drug combination for first line therapy by examining tumor and peripheral blood...

Sponsor: John KirkwoodEnrolling: 201 location
RECRUITINGNCT04792463

Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome

This research will have a significant impact on the overall management of those cancer patients and their family members who are at risk for hereditary cancer due to germline...

Sponsor: Mohamed Abdel-RahmanEnrolling: 5001 location
RECRUITINGNCT06536257

Personalised Immunotherapy Platform

This is a non-interventional study to prospectively test a suite of predictive biomarker models of immunotherapy resistance in patients with melanoma, non-melanoma skin cancers...

Sponsor: Melanoma Institute AustraliaEnrolling: 10003 locations
RECRUITINGNCT07407166

Efficacy of First-Line Immunotherapy in Metastatic Melanoma in Slovenia and Identification of Predictive Biomarkers

This study evaluates the effectiveness of first-line immunotherapy in patients with metastatic melanoma treated at the Institute of Oncology Ljubljana in Slovenia. The main...

Sponsor: Institute of Oncology LjubljanaEnrolling: 401 location
RECRUITINGPhase 3NCT05727904

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With...

This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared...

Sponsor: Iovance Biotherapeutics, Inc.Enrolling: 67020 locations
RECRUITINGNCT05794035

Impact of Hypofractionated Radiotherapy Strategy After Surgery of Skin Carcinomas in Older Patients

Non-melanoma skin cancer (NMSC) incidence as well as morbidity rates are high in older patients. Surgery is the standard of care. About 5 to 10% of NMSC present high-risk...

Sponsor: Assistance Publique - Hôpitaux de ParisEnrolling: 3031 location
RECRUITINGPhase 2NCT03563729

Melanoma Metastasized to the Brain and Steroids

This clinical trial is to clarify whether treatment with a checkpoint inhibitor alone (pembrolizumab) or two in combination (ipilimumab and nivolumab), results in clinical benefit...

Sponsor: Inge Marie SvaneEnrolling: 803 locations
RECRUITINGNCT04095195

Registry of Subjects at Risk of Pancreatic Cancer

IRFARPC is a multicenter national registry designed to study the diagnosis and predisposing factors of subjects with an inherited increased risk for pancreatic cancer.

Sponsor: Associazione Italiana per lo Studio del PancreasEnrolling: 10004 locations
RECRUITINGPhase 1 / Phase 2NCT05379985

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.

Sponsor: Revolution Medicines, Inc.Enrolling: 75420 locations
RECRUITINGPhase 1NCT05562791

A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer

The purpose of this study is to see whether 68Gallium PSMA-PET/CT scans are an effective way to detect sites of cancer in people with metastatic bladder cancer or skin cancer. The...

Sponsor: Memorial Sloan Kettering Cancer CenterEnrolling: 207 locations
RECRUITINGNCT05797415

Sentinel Lymph Node Biopsy in Ocular Surface and Adnexal Cancers

The study involves enrollment of patients with sebaceous carcinoma, Merkel's carcinoma, Porocarcinoma, Melanoma, and squamous cell Ca of the ocular surface and adnexa both primary...

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 251 location
RECRUITINGNCT04693377

Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME...

This trial compares cryoablation combined with stereotactic body radiation therapy to stereotactic body radiation therapy alone to see how well they work in treating patients with...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 401 location
RECRUITINGPhase 1 / Phase 2NCT01898039

Modified Vaccine for High Risk or Low Residual Melanoma Patients

This study is designed for patients who had malignant melanoma and, following tumor removal, are now free of disease, or have only very minor residual disease, and are at a very...

Sponsor: Hadassah Medical OrganizationEnrolling: 501 location
RECRUITINGNCT06861023

Review of the Literature and Serie of Patients Who Underwent Reconstruction After Wide Local Excision of Nail Apparatus...

Melanomas of the nail bed are often diagnosed at the locally advanced stage. The standard treatment was amputation of the finger or toe, but it has now been established that...

Sponsor: Centre Hospitalier Universitaire de NiceEnrolling: 101 location
RECRUITINGNCT07225036

Promoting Immunotherapy Efficacy With Low-Dose Liver RT

The purpose of this study is to see if adding Low-Dose Liver Radiation (LD-LRT) improves progression free survival (PFS). This study is for patients with either melanoma or...

Sponsor: Jordan KharofaEnrolling: 211 location
RECRUITINGPhase 2NCT06932757

Adjuvant Quisinostat in High-Risk Uveal Melanoma

The purpose of this study is to see if giving participants quisinostat will prevent participants' uveal melanoma tumor from spreading. The researchers want to find out the effects...

Sponsor: University of MiamiEnrolling: 631 location

Showing 50 of 108 trials.Search all Melanoma trials

Frequently Asked Questions

There are currently 108 clinical trials for Melanoma, with 108 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Melanoma, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 7 Phase 3 trials for Melanoma, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.